/ESPR
ESPR Stock - Esperion Therapeutics, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$3.30-7.04%
$0.25 (-7.04%) • Jan 13
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+172.7%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ESPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.27 – $3.33
TARGET (TP)$9.00
STOP LOSS$3.04
RISK/REWARD1:21.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$4.18
52W Low$0.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $332.31M | $116.33M | $75.47M | $78.45M | $227.55M |
| Gross Profit | $263.71M | $73.07M | $48.51M | $64.23M | $225.16M |
| Gross Margin | 79.4% | 62.8% | 64.3% | 81.9% | 98.9% |
| Operating Income | $54.40M | $-155,563,000 | $-179,501,000 | $-226,730,000 | $-121,396,000 |
| Net Income | $-51,745,000 | $-209,248,000 | $-233,659,000 | $-269,108,000 | $-143,551,000 |
| Net Margin | -15.6% | -179.9% | -309.6% | -343.0% | -63.1% |
| EPS | $-0.28 | $-2.03 | $-4.33 | $-11.03 | $-6.05 |
Company Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ESPRBeat Rate
72%
Last 18 quarters
Avg Surprise
+41.3%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+5.7%
$-0.50vs$-0.53
Q2 24
+580.0%
$0.34vs$0.05
Q3 24
+66.7%
$-0.05vs$-0.15
Q4 24
-7.1%
$-0.15vs$-0.14
Q1 25
+28.6%
$-0.10vs$-0.14
Q2 25
-16.7%
$-0.21vs$-0.18
Q3 25
+88.2%
$-0.02vs$-0.17
Q4 25
-77.8%
$-0.16vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $0.15 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.09 | $-0.16 | -77.8% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.17 | $-0.02 | +88.2% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.15 | $-0.05 | +66.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.05 | $0.34 | +580.0% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.63 | $-0.46 | +27.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.65 | $-0.79 | -21.5% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-0.87 | $-0.76 | +12.6% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-0.93 | $-0.81 | +12.9% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.95 | $-1.05 | -10.5% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.96 | $-0.93 | +3.1% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-2.32 | $-1.77 | +23.7% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-2.86 | $-2.62 | +8.4% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-1.82 | $-1.67 | +8.2% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ESPR
What is ESPR's current stock price?
Esperion Therapeutics, Inc. (ESPR) is currently trading at $3.30 per share. The stock has moved -7.04% today.
What is the analyst price target for ESPR?
The average analyst price target for ESPR is $9.00, based on 1 analyst.
What sector is Esperion Therapeutics, Inc. in?
Esperion Therapeutics, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ESPR's market cap?
Esperion Therapeutics, Inc. has a market capitalization of $0.65 billion, making it a small-cap company.
Does ESPR pay dividends?
No, Esperion Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.31
Mkt Cap: $0.5B
AQST
Aquestive Therapeutics, Inc.
$3.42
Mkt Cap: $0.3B
CRVS
Corvus Pharmaceuticals, Inc.
$6.50
Mkt Cap: $0.5B
EBS
Emergent BioSolutions Inc.
$12.17
Mkt Cap: $0.7B
OFIX
Orthofix Medical Inc.
$14.81
Mkt Cap: $0.6B
OLMA
Olema Pharmaceuticals, Inc.
$27.89
Mkt Cap: $1.9B
RGNX
REGENXBIO Inc.
$15.05
Mkt Cap: $0.8B
SIGA
SIGA Technologies, Inc.
$6.60
Mkt Cap: $0.5B
SNDL
SNDL Inc.
$1.65
Mkt Cap: $0.4B
VTYX
Ventyx Biosciences, Inc.
$13.86
Mkt Cap: $1.0B
Explore stocks similar to ESPR for comparison